Abstract
To assess the efficacy of various doses of Mildronate in combination with standard therapy for the exercise tolerance of patients with stable angina pectoris. The primary efficacy variable was the change in exercise time in bicycle ergometry from the baseline to 12 weeks of treatment. The secondary endpoints were the changes in maximum achieved load and time to the onset of angina from the baseline to week 12. A total of 512 patients with chronic coronary heart disease who had ischemia as the limiting factor in the exercise test from 72 study centers in 4 countries were enrolled in this prospective, randomized, double-blind, placebo controlled phase 2 study. The patients were assigned to either 4 groups receiving standard therapy plus Mildronate at different daily doses or 1 group receiving standard therapy plus placebo. The mean change in the total exercise time in the mildronate 100 mg and mildronate 300 mg groups was -2.12±108.45 and 11.48±62.03 seconds, respectively. The mean change for the placebo group was -7.10±81.78 seconds. The difference between Mildronate 100 mg and 300 mg and placebo groups was not significant. Patients in the Mildronate 1000 mg group showed a remarkable increase in the mean change in the total exercise time (35.18±53.29 seconds, P=0.002). Mildronate at a dose of 3000 mg caused a smaller increase as compared with a dose of 1000 mg. Similar changes in the secondary end parameters were observed. The most effective dose of Mildronate in combination with standard therapy was found to be 500 mg twice a day.
Highlights
A possible alternative of medical treatment of ischemic conditions is the use of pharmaceutical products having so-called “metabolic” activity, i.e., products acting mainly on selected mechanisms of tissue energetic metabolism
Patients in the Mildronate 1000 mg group showed a remarkable increase in the mean change in the total exercise time (35.18±53.29 seconds, P=0.002)
Mildronate at a dose of 3000 mg caused a smaller increase as compared with a dose of 1000 mg
Summary
A possible alternative of medical treatment of ischemic conditions is the use of pharmaceutical products having so-called “metabolic” activity, i.e., products acting mainly on selected mechanisms of tissue energetic metabolism. Mildronate, a partial inhibitor of fatty acid oxidation (p-FOX), is the representative of this group of pharmaceutical products. Mildronate is a structural aza-analogue of the carnitine precursor gamma-butyrobetaine (GBB). It inhibits carnitine biosynthesis reversibly competing for gamma-butyrobetaine hydroxylase. Carnitine is not reabsorbed into the circulatory system to re-enter metabolic pathways, but is directly eliminated from the organism. This results in reduced tissue [2] and plasma [3] concentrations of carnitine. Thereby, long-chain fatty acid transport through internal mitochondrial membranes is inhibited. In turn, further enhances the transport of entire ATP produced in cytosol and delayed β-oxidation of fatty acids, and
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.